Released Nov 4, 2021, after the close
10-Q filed Nov 4, 2021, 35 days after period end · 0000950170-21-003066
Q3 2021 · 10-Q
Revenue$14.23M$14.23M +88.2% vs Q3 2020+6.1% vs Q2 2021
Net Income-$43.31M-$43.31M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.45-$0.45 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$54,623,000N/M
Operating Cash Flowderived-$33,375,000N/M
Free Cash Flowderived-$48,110,000N/M
Margins · derived
Operating margin-384.0%+32.6 pt vs Q3 2020
Net margin-304.4%+472.0 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $14.23M | $7.56M | $2.43M | $1.03M |
| Net Income | -$43.31M | -$58.68M | -$26.61M | -$16.78M |
| EPS Diluted | -$0.45 | -$0.68 | -$0.40 | -$0.31 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR